Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 6 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Aug 28, 2026 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Merck Sharp & Dohme LLC
- Interventions being studied
- Biological: pembrolizumab/vibostolimab; Biological: durvalumab; Drug: cisplatin; Drug: pemetrexed; Drug: etoposide; Drug: carboplatin; Drug: paclitaxel; Radiation: thoracic radiotherapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
The main inclusion and
- include but are not limited to the following: Inclusion Criteria
- Has pathologically (histologically or cytologically) confirmed diagnosis of NSCLC.
- Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8
- Is determined to have unresectable, Stage III NSCLC as documented by a multidisciplinary tumor board or by the treating physician in consultation with a thoracic surgeon
- Has no evidence of metastatic disease, indicating Stage IV NSCLC, in whole-body fluorodeoxyglucose (FDG)-positron emission tomography (PET) or FDG-PET/ computed tomography (CT) and CT or magnetic resonance imaging (MRI) scans of diagnostic quality of chest, abdomen, pelvis and brain
- Has measurable disease as defined by RECIST 1.1, with at least 1 lesion being appropriate for selection as a target lesion, as determined by local site investigator/radiology review
- Has not received prior treatment (chemotherapy, targeted therapy, or radiotherapy) for their Stage III NSCLC
- Has provided tumor tissue sample (tissue biopsy \[core, incisional, or excisional\])
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 assessed within 7 days prior to the first administration of study intervention
- Has a life expectancy of at least 6 months
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- VA Long Beach Healthcare System ( Site 2831)Long Beach, California
- VA West Los Angeles Medical Center ( Site 2808)Los Angeles, California
- Millennium Oncology Research Clinic ( Site 2801)Hollywood, Florida
- Mid Florida Hematology and Oncology Center ( Site 2800)Orange City, Florida
- Moffitt Cancer Center ( Site 2818)Tampa, Florida
- University of Chicago Medical Center ( Site 2828)Chicago, Illinois
- Franciscan St. Francis Health ( Site 2812)Indianapolis, Indiana
- MFSMC-HJWCI ( Site 2804)Baltimore, Maryland
- Boston Medical Center ( Site 2829)Boston, Massachusetts
- University of Massachusetts Chan Medical School ( Site 2815)Worcester, Massachusetts
- University of Missouri Hospital ( Site 2839)Columbia, Missouri
- Cox Medical Center North-Cox Medical Center/Hulston Cancer Center/ Radiation Oncology ( Site 2837)Springfield, Missouri
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 28, 2026. Always confirm current availability with the study team.